Delving into the Latest Updates on Human fibrinogen (Shanxi Kangbao Biological Product Co. Ltd.) with Synapse

Overview

Basic Info

Drug Type

Non-recombinant coagulation factor

Synonyms-

Target

Fibrinogen

Mechanism

Fibrinogen stimulants

Therapeutic Areas

Congenital DisordersHemic and Lymphatic DiseasesOther Diseases

Active Indication

Afibrinogenemia

Inactive Indication-

Originator Organization

Shanxi Kangbao Biological Product Co. Ltd.

Active Organization

Shanxi Kangbao Biological Product Co. Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

CN (13 Sep 2021),

Afibrinogenemia

Regulation-

Login to view timeline

The final results of long-term continuous treatment with human GH in patients with growth hormone deficiency (GHD) are described. Untreated patients with isolated idiopathic GHD average about -6 SD height at maturity; our patients averaged about -2 SD. The statistics appear to show that what is important is starting treatment before the child has fallen much below the normal centiles for height and this usually means before age two or three in idiopathic cases. Ascertainment through an effective system of primary care is more important than an elaboration treatment schedules.

100 Deals associated with Human fibrinogen (Shanxi Kangbao Biological Product Co. Ltd.)

Login to view more data